-
Founded in:
1992-07-30 -
Country:
China -
Address:
7km west of Wuhua District, Kunming City, Yunnan Province -
Tax NO.:
915300006226003939 -
Registered Funds:
$8,527,898 -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Atinol |
A selective β1-adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility.
More
A selective β1-adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Atinol |
A selective β1-adrenergic receptor blocker that does not have membrane stabilizing effects and endogenous sympathomimetic activity, but does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility.
More
A selective β1-adrenergic receptor blocker that does not have membrane stabilizing effects and endogenous sympathomimetic activity, but does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 2-(acetoxy)benzoic acid |
This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects
More
This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| (+/-)-Verapamil hydrochloride |
Calcium ion antagonists exert their pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells, but do not change the serum calcium concentration. They dilate the main coronary arteries and arterioles in normal and ischemic parts of the heart, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase myocardial oxygen delivery in patients with coronary artery spasm, relieve and prevent coronary artery spasm; reduce total peripheral resistance and reduce myocardial oxygen consumption. They can be used to treat variant angina and unstable angina. They reduce the influx of calcium ions, prolong the effective refractory period of the atrioventricular node, and slow down conduction.
More
Calcium ion antagonists exert their pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells, but do not change the serum calcium concentration. They dilate the main coronary arteries and arterioles in normal and ischemic parts of the heart, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase myocardial oxygen delivery in patients with coronary artery spasm, relieve and prevent coronary artery spasm; reduce total peripheral resistance and reduce myocardial oxygen consumption. They can be used to treat variant angina and unstable angina. They reduce the influx of calcium ions, prolong the effective refractory period of the atrioventricular node, and slow down conduction. |
152-11-4 | 13 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bengenin |
It has good antitussive and expectorant effects on chronic bronchitis
More
It has good antitussive and expectorant effects on chronic bronchitis |
125mg | 477-90-7 | 0 |
| Chlorphenamine maleate |
It has a strong histamine H1 receptor blocking effect, can alleviate other respiratory symptoms caused by allergies, and also has a mild inhibitory effect on the central nervous system
More
It has a strong histamine H1 receptor blocking effect, can alleviate other respiratory symptoms caused by allergies, and also has a mild inhibitory effect on the central nervous system |
2mg | 113-92-8 | 28 |